Monte Rosa Therapeutics Inc. (GLUE) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Monte Rosa Therapeutics I...

    NASDAQ: GLUE · Real-Time Price · USD
    4.85
    -0.15 (-3.00%)
    At close: Sep 04, 2025, 12:24 PM

    Monte Rosa Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 75.62M n/a n/a n/a
    Cost of Revenue
    		 8.12M 6.22M 8.56M 2.13M
    Gross Profit
    		 67.5M -6.22M -8.56M -2.13M
    Operating Income
    		 -81.11M -143.31M -112.38M -72.88M
    Interest Income
    		 10.57M 9.33M 3.76M 46K
    Pretax Income
    		 -70.13M -135.01M -108.5M -73.96M
    Net Income
    		 -72.7M -135.35M -108.5M -73.96M
    Selling & General & Admin
    		 35.17M 32.04M 27.32M 15.73M
    Research & Development
    		 121.56M 105.05M 85.06M 57.16M
    Other Expenses
    		 -8.12M n/a n/a n/a
    Operating Expenses
    		 148.61M 137.09M 112.38M 72.88M
    Interest Expense
    		 n/a n/a 3.76M n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 156.73M 143.31M 112.38M 72.88M
    Income Tax Expense
    		 2.57M 338K n/a n/a
    Shares Outstanding (Basic)
    		 73.91M 51.4M 47.23M 46.54M
    Shares Outstanding (Diluted)
    		 73.91M 51.4M 47.23M 46.54M
    EPS (Basic)
    		 -0.98 -2.63 -2.3 -1.59
    EPS (Diluted)
    		 -0.98 -2.63 -2.3 -1.59
    EBITDA
    		 -72.99M -137.09M -108.64M -70.75M
    EBIT
    		 -81.11M -143.31M -108.5M -73.96M
    Depreciation & Amortization
    		 8.12M 6.22M 3.75M 2.13M

    Add to Watchlist